Vol 4, No 1 (March 30, 2015): Chinese Clinical Oncology (Lymphoma - Guest Editors: Bruce D. Cheson and Jun Zhu)

News

Chinese Clinical Oncology is now indexed by PubMed/MEDLINE: a big step forward
Helen Seliman, Grace S. Li
Chinese Clinical Oncology  
2015;
4
(1)
:1
.

Preface

Lymphoma: looking from the present to the future
Bruce D. Cheson, Jun Zhu
Chinese Clinical Oncology  
2015;
4
(1)
:2
.

Review Article

Pitfalls in the pathological diagnosis of lymphoma
Xianghong Li
Chinese Clinical Oncology  
2015;
4
(1)
:3
.
PET/CT: appropriate application in lymphoma
Xuejuan Wang
Chinese Clinical Oncology  
2015;
4
(1)
:4
.
Staging and response assessment in lymphomas: the new Lugano classification
Bruce D. Cheson
Chinese Clinical Oncology  
2015;
4
(1)
:5
.
Radiotherapy in early stage classical Hodgkin lymphoma: past, present and future
Weijing Zhang
Chinese Clinical Oncology  
2015;
4
(1)
:6
.
Individualized management of follicular lymphoma
Bing Bai, Hui-Qiang Huang
Chinese Clinical Oncology  
2015;
4
(1)
:7
.
Mantle cell lymphoma-management in evolution
Saurabh Rajguru, Brad S. Kahl
Chinese Clinical Oncology  
2015;
4
(1)
:8
.
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges
Jonathan W. Friedberg
Chinese Clinical Oncology  
2015;
4
(1)
:9
.
Primary extranodal B-cell lymphoma: current concepts and treatment strategies
Barbara Vannata, Emanuele Zucca
Chinese Clinical Oncology  
2015;
4
(1)
:10
.
New approaches in primary central nervous system lymphoma
Eleanor Fraser, Katherine Gruenberg, James L. Rubenstein
Chinese Clinical Oncology  
2015;
4
(1)
:11
.
Extranodal natural killer/T cell lymphoma: we should and we can do more
Zhitao Ying, Jun Zhu
Chinese Clinical Oncology  
2015;
4
(1)
:12
.
Risk- and response-adapted strategies for the management of Hodgkin lymphoma
Marcus Remer, Peter W. M. Johnson
Chinese Clinical Oncology  
2015;
4
(1)
:13
.
New drugs for the treatment of non-Hodgkin lymphomas
Sonali M. Smith
Chinese Clinical Oncology  
2015;
4
(1)
:14
.

Meet the Professor

Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma
Shannon Zhang
Chinese Clinical Oncology  
2015;
4
(1)
:15
.
Professor Jon Wigginton: where we are standing in immunotherapy
Grace S. Li
Chinese Clinical Oncology  
2015;
4
(1)
:16
.

Disclosure:

The focused issue “Lymphoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Bruce D. Cheson and Jun Zhu served as the unpaid Guest Editors for the focused issue.